Characterization of molecular targets of therapy in non-small cell lung cancer (NSCLC) utilizing a liquid biopsy.

LATEST NEWS Epic Sciences Expands Executive Leadership Team - Appoints Joel Smith as Chief Financial Officer and General Counsel Read More

LATEST NEWS Epic Sciences to Present New Data Showing Feasibility of Its Liquid Biopsy Test in Breast Cancer Read More

LATEST NEWS Liquid Biopsy Technologies Diversify in Expanding CTC Field Read More